2022
688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC)
Moutafi M, Economopoulou P, Kotsantis I, Anastasiou M, Foukas P, Fountzilas G, Rimm D, Psyrri A. 688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s857-s858. DOI: 10.1016/j.annonc.2022.07.812.Peer-Reviewed Original Research
2019
Corrigendum to “Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma” [Oral Oncol. 86 (2018) 278–287]
Hartman DJ, Ahmed F, Ferris RL, Rimm DL, Pantanowitz L. Corrigendum to “Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma” [Oral Oncol. 86 (2018) 278–287]. Oral Oncology 2019, 93: 129. PMID: 31053366, DOI: 10.1016/j.oraloncology.2019.04.016.Peer-Reviewed Original Research
2018
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens
Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. Npj Breast Cancer 2018, 4: 32. PMID: 30211313, PMCID: PMC6123433, DOI: 10.1038/s41523-018-0084-4.Peer-Reviewed Original ResearchEstrogen receptor statusInvasive ductal carcinomaER statusEstrogen receptorReceptor statusPercent of cellsHormonal therapyDuctal carcinomaImmunohistochemistry stainingHistology patternPathway statusPatient samplesPathway activationPilot studyNuclear featuresDeep neural networksTissue coresNeural networkReceptorsFuture studiesStatusTissue morphologyBiological featuresDeep learning approachCarcinomaMultiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).
Henick B, Datar I, Villarroel-Espindola F, Sanmamed M, Yu J, Tuktamyshov R, Li A, Toki M, Syrigos K, Rimm D, Chen L, Herbst R, Schalper K. Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). Journal Of Clinical Oncology 2018, 36: 12002-12002. DOI: 10.1200/jco.2018.36.15_suppl.12002.Peer-Reviewed Original Research
2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D’Alfonso T, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R, Cancer O. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars In Cancer Biology 2017, 52: 16-25. PMID: 29024776, DOI: 10.1016/j.semcancer.2017.10.003.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerResidual diseaseTIL assessmentDuctal carcinomaInternational Immuno-Oncology Biomarker Working GroupBiomarker Working GroupClinical breast cancer researchBreast cancer researchNeoadjuvant chemotherapyNeoadjuvant therapyImmunotherapeutic strategiesImmunological biomarkersInvasive carcinomaClinical trialsClinical relevanceConsensus guidanceInternational guidelinesCarcinomaWorking GroupCancerDiseaseMorphological evaluationLymphocytesCancer researchObjective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAfatinibAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCohort StudiesExtracellular SpaceFemaleFluorescent Antibody TechniqueHumansIntracellular SpaceLapatinibMaytansineMiddle AgedNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsProtein DomainsQuinazolinesReceptor, ErbB-2Retrospective StudiesTissue Array AnalysisTrastuzumabUterine NeoplasmsConceptsUterine serous carcinomaOvarian serous carcinomaHER2 intracellular domainSerous carcinomaECD levelsECD statusTissue microarrayHER2 measurementQuantitative immunofluorescenceHER2 overexpression/amplificationClinico-pathologic characteristicsClinico-pathological featuresHER2-targeted agentsIntracellular domainOverexpression/amplificationHER2 extracellular domainExtracellular domainOSC patientsClinical trialsBreast cancerClinical significancePatientsHER2 assaysP95-HER2Carcinoma
2015
Correlation of miR200a expression with survival in patients with small, lymph node negative head and neck squamous cell carcinoma.
Vasilakopoulou M, Hanna J, Rampias T, Perisanidis C, Rimm D, Psyrri A. Correlation of miR200a expression with survival in patients with small, lymph node negative head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2015, 33: e17062-e17062. DOI: 10.1200/jco.2015.33.15_suppl.e17062.Peer-Reviewed Original Research
2014
Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma
Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. The Journal Of Clinical Endocrinology & Metabolism 2014, 100: e493-e502. PMID: 25490274, PMCID: PMC5393505, DOI: 10.1210/jc.2014-3282.Peer-Reviewed Original ResearchConceptsAdrenocortical carcinomaSomatic mutationsCopy number alterationsNumber alterationsNonsynonymous somatic mutationsWnt pathway dysregulationHomozygous deletionMajority of casesPotential disease-causing mutationsWhole-exome sequencingUnderlying somatic mutationsLethal malignancyPathway dysregulationTumorsExome sequencingFocal CNAsDisease-causing mutationsCarcinomaTERT locusZNRF3Recurrent CNAsAlterationsNormal samplesTP53Unknown role
2013
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
Velcheti V, Rimm DL, Schalper KA. Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal Of Thoracic Oncology 2013, 8: 803-805. PMID: 23676558, PMCID: PMC3703468, DOI: 10.1097/jto.0b013e318292be18.Peer-Reviewed Original ResearchConceptsDeath ligand 1Sarcomatoid carcinomaCell lung carcinomaLung carcinomaPD-L1PD-1/PD-L1 axisPD-1/PD-L1 pathwayProgrammed Death Ligand 1PD-L1 protein expressionEffector immune responsesPD-L1 axisPD-L1 pathwayLung sarcomatoid carcinomaLung cancer cohortSarcomatoid lung carcinomasLigand 1Mouse monoclonal antibodyDeath-1Lymphocytic infiltrationRare subtypeSuch therapyCancer cohortT cellsCarcinomaTumor types
2011
p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Ghebremichael M, Pectasides E, Dimou A, Burtness B, Rimm D, Wanebo H, Forastiere A. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2011, 29: e16032-e16032. DOI: 10.1200/jco.2011.29.15_suppl.e16032.Peer-Reviewed Original ResearchOptimal tumor sampling for immunostaining of biomarkers in breast carcinoma
Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Research 2011, 13: r51. PMID: 21592345, PMCID: PMC3218938, DOI: 10.1186/bcr2882.Peer-Reviewed Original ResearchConceptsWhole tissue sectionsBreast carcinomaEstrogen receptorBiomarker expressionTumor biomarker expressionAmount of tumorTissue sectionsEvidence-based standardsHeterogeneous markersTherapeutic responseHER-2Optimal tumorBreast biopsyBreast tumorsClinical implicationsMAP-tauQuantitative immunofluorescenceClinical useLevel of expressionCarcinomaImmunostaining assaysBiomarkersTumorsTissue samplesBiomarker heterogeneity
2010
Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA.
Pectasides E, Fountzilas G, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Rimm D, Burtness B, Psyrri D. Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. Journal Of Clinical Oncology 2010, 28: 5538-5538. DOI: 10.1200/jco.2010.28.15_suppl.5538.Peer-Reviewed Original ResearchThe prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss.
Fountzilas G, Pectasides E, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Pectasides D, Rimm D, Burtness B, Psyrri D. The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. Journal Of Clinical Oncology 2010, 28: 5550-5550. DOI: 10.1200/jco.2010.28.15_suppl.5550.Peer-Reviewed Original Research
2006
Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma
Yang XR, Charette LA, Garcia-Closas M, Lissowska J, Paal E, Sidawy M, Hewitt SM, Rimm DL, Sherman ME. Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2006, 15: 157-161. PMID: 16932071, DOI: 10.1097/01.pdm.0000213453.45398.e0.Peer-Reviewed Original ResearchConceptsTerminal duct lobular unitsTissue microarrayEstrogen receptorDuctal carcinomaProgesterone receptorBreast cancerLobular unitsLarge case-control studyPR expression levelsCase-control studyInvasive breast carcinomaPercentage of tubulesInvasive carcinomaEpithelial lesionsBreast carcinomaImmunohistochemical characterizationImmunohistochemical stainingPeritumoral tissuesPositive stainingScoring systemCarcinomaCategorical scoring systemBreast tissueMethodologic studyExpression levelsReciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma
Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006, 25: 6959-6967. PMID: 16715134, DOI: 10.1038/sj.onc.1209682.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCadherinsCell Line, TumorColonic NeoplasmsEnzyme ActivationEpithelial CellsHumansImmunohistochemistryImmunoprecipitationNeoplasm InvasivenessPrognosisPromoter Regions, GeneticProto-Oncogene Protein c-ets-1Reverse Transcriptase Polymerase Chain ReactionRho GTP-Binding ProteinsRhoA GTP-Binding ProteinRhoC GTP-Binding ProteinRNA, Small InterferingTranscription, GeneticConceptsColon carcinomaRhoC expressionPrognostic markerRhoC protein expressionE-cadherinET-1 binding sitesClinical outcomesPoor outcomeColon cancer cellsColorectal tumorsET-1Colon cancerUse of shRNAMesenchymal transitionExpression correlatesCarcinomaAberrant expressionHigh expressionProtein expressionCancer cellsMesenchymal characteristicsEMTSubsequent activationReciprocal regulationCell migration
2002
Quantitative examination of mechanophysical tumor cell enrichment in fine‐needle aspiration specimens
Ernst LM, Rimm DL. Quantitative examination of mechanophysical tumor cell enrichment in fine‐needle aspiration specimens. Cancer 2002, 96: 275-279. PMID: 12378594, DOI: 10.1002/cncr.10746.Peer-Reviewed Original ResearchConceptsFine-needle aspirationBreast carcinomaMalignant cellsSurgical excisionHistologic sectionsDiagnostic fine needle aspirationNontumor cellsSurgical excision specimensChi-square testTumor cell enrichmentExcision specimensFNA specimensCurrent studyFNA specimenCarcinomaCDNA microarrayRepresentative slidesNonmalignant cellsThinPrep preparationsTotal cellsTissue sectionsCell enrichmentTumorsExcisionCells
2001
β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis
Garcia-Rostan G, Camp R, Herrero A, Carcangiu M, Rimm D, Tallini G. β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis. American Journal Of Pathology 2001, 158: 987-996. PMID: 11238046, PMCID: PMC1850336, DOI: 10.1016/s0002-9440(10)64045-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaAdultAgedBeta CateninBiomarkers, TumorCarcinomaCell DivisionCell NucleusCytoskeletal ProteinsDown-RegulationExonsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedOncogene Protein p21(ras)PhenotypePoint MutationPolymorphism, Single-Stranded ConformationalPrognosisSurvival RateThyroid NeoplasmsTrans-ActivatorsConceptsPoor prognosisTumor differentiationBeta-catenin expressionConventional prognostic indicatorsAggressive tumor phenotypeNuclear beta-catenin localizationThyroid tumor samplesBeta-catenin dysregulationAberrant nuclear expressionΒ-catenin dysregulationDifferentiated tumorsPrognostic indicatorThyroid cancerThyroid neoplasmsNuclear immunoreactivityBeta-catenin alterationsNuclear expressionTumor samplesProgressive lossCarcinomaTumor phenotypeSingle-strand conformational polymorphismBeta-catenin mutationsHuman cancersDown regulation
2000
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp R, Charette L, Rimm D. Validation of Tissue Microarray Technology in Breast Carcinoma. Laboratory Investigation 2000, 80: 1943-1949. PMID: 11140706, DOI: 10.1038/labinvest.3780204.Peer-Reviewed Original ResearchConceptsWhole tissue sectionsInvasive breast carcinomaBreast carcinomaTissue microarray technologyLarge-scale retrospective cohort studyTissue sectionsArchival tissueRetrospective cohort studyHER2/neu oncogeneTissue microarray techniqueCohort studyBreast cancer microarrayProgesterone receptorArchival cohortEstrogen receptorAmount of tissueCommon antigenNeu oncogeneEntire tumorCarcinomaProtein expressionProtein expression patternsArchival formalinTissueReceptors